Search company, investor...

Intarcia Therapeutics

intarcia.com

Founded Year

1995

Stage

Debt - VI | Alive

Total Raised

$1.487B

Valuation

$0000 

Last Raised

$198.5M | 4 yrs ago

About Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Headquarters Location

One Marina Park Drive 13th Floor

Boston, Massachusetts, 02210,

United States

617-936-2500

Missing: Intarcia Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intarcia Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Intarcia Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Intarcia Therapeutics in 1 CB Insights research brief, most recently on Jan 11, 2023.

Expert Collections containing Intarcia Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intarcia Therapeutics is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,205 items

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health IT

7,901 items

Intarcia Therapeutics Patents

Intarcia Therapeutics has filed 83 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Drug delivery devices
  • Peptide hormones
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2018

8/30/2022

Technical drawing, Graphical projections, Cuttlefish, Honeycombs (geometry), Goldfish breeds

Grant

Application Date

10/23/2018

Grant Date

8/30/2022

Title

Related Topics

Technical drawing, Graphical projections, Cuttlefish, Honeycombs (geometry), Goldfish breeds

Status

Grant

Latest Intarcia Therapeutics News

Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA denied

Aug 31, 2022

Zachary Brennan Senior Editor The last members of its executive team have moved on, the phone number at its Boston-based HQ has been shut off, and as of earlier this month, the FDA has denied Intarcia Therapeutics’ final request for a hearing to re-review the company’s twice-rejected type 2 diabetes drug candidate and proprietary delivery system. The letter from the FDA earlier this month caps a nearly five-year saga from when the FDA first rejected Intarcia’s twice-yearly type 2 diabetes drug, known as ITCA 650, after calling on the company to address extensive clinical deficiencies, and device and product quality-related issues. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Right on the heels of an EMA recommendation for EU approval, Sanofi has scooped up the FDA’s OK for the first approved therapy to treat symptoms that are not related to the central nervous system in patients with acid sphingomyelinase deficiency, which includes a range of ailments under the umbrella for Niemann-Pick disease. For Sanofi, the approval of the enzyme replacement therapy Xenpozyme (Olipudase alfa) marks a key win for Paul Hudson’s strategy to beef up their rare disease portfolio, but this one has been a long time coming. Sanofi picked up the drug after the 2011 acquisition of Genzyme and posted positive pivotal data two and a half years ago. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor It’s the most wonderful time of the year — for media planners that is. The annual ad strategy and brand planning for next year are in full swing, and Nancy Phelan, a former pharma commercial leader at Pfizer and Bristol Myers Squibb, has “radical” ideas about how it needs to evolve. Phelan, now an SVP at Indegene, is aiming to disrupt the status quo in timing, and update both the process and the thinking that goes into brand planning. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Obesity is in the spotlight thanks to a raft of new and pending therapies in the pipeline. However, Currax Pharmaceuticals’ Contrave, the old guard of weight loss meds, isn’t ceding its veteran status. In fact, it’s doubling down on Contrave as an option with the launch of a new brand campaign “One Size Does Not Fit All.” The digital effort highlights the idea that different solutions fit different people, and includes the brand website along with digital and social media ads and posts, medical journal ads and education and in-office materials. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor A California judge yesterday sided with a stem cell clinic chain against the FDA, setting shock waves through the agency as it potentially has to rework how it enforces these clinics moving forward. Judge Jesus Bernal ruled in federal court in California’s Central District against the FDA’s argument that a group of stem cell clinics called the Cell Surgical Network, led by Mark Berman and Elliot Lander, were selling unapproved drug products in the form of adipose, or fat, cell mixtures. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Max Gelman Senior Editor Looking to build out a case for its drugs that can better penetrate the blood-brain barrier, Denali Therapeutics touted new interim Hunter syndrome data Wednesday morning. And execs are sharpening their regulatory pitch. The South San Francisco biotech reported longer-term results from a Phase I/II study evaluating DNL310, saying the safety profile remained similar to the current standard of care — enzyme replacement therapy — after 85 weeks. Additionally, a larger group of patients gives the company more confidence that early biomarker results from July 2021 indicate the drug is positively affecting Hunter syndrome patients. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Lumakras, Amgen’s groundbreaking KRAS drug, was approved on data from an open-label, single-arm study suggesting, among other things, median progression-free survival of 6.8 months for patients with KRASG12C-mutated non-small cell lung cancer. Now, Amgen says it has the first proof that Lumakras beats chemotherapy — the current standard of care — on that metric. Further analyses are still ongoing and data will be reserved for future medical conferences, Amgen said, remaining tight-lipped. What it will say is that the drug, formerly known as sotorasib, met the primary endpoint of PFS in the CodeBreaK 200 trial, where it went head to head with intravenous docetaxel. Among 345 patients, Lumakras demonstrated “statistical significance and superiority” over the chemo. Keep reading Endpoints with a free subscription Unlock this story instantly and join 149,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP

Intarcia Therapeutics Frequently Asked Questions (FAQ)

  • When was Intarcia Therapeutics founded?

    Intarcia Therapeutics was founded in 1995.

  • Where is Intarcia Therapeutics's headquarters?

    Intarcia Therapeutics's headquarters is located at One Marina Park Drive, Boston.

  • What is Intarcia Therapeutics's latest funding round?

    Intarcia Therapeutics's latest funding round is Debt - VI.

  • How much did Intarcia Therapeutics raise?

    Intarcia Therapeutics raised a total of $1.487B.

  • Who are the investors of Intarcia Therapeutics?

    Investors of Intarcia Therapeutics include Bill & Melinda Gates Foundation, Baupost Group, Foresite Capital, RA Capital Management, Shandong Luxin Investment Holdings Group and 35 more.

  • Who are Intarcia Therapeutics's competitors?

    Competitors of Intarcia Therapeutics include Horizon Therapeutics, Diasome Pharmaceuticals, Zosano Pharma, Zogenix, Adamas Pharmaceuticals, Annovis Bio, Embera NeuroTherapeutics, CoImmune, Metabolic Solutions Development, TxCell and 84 more.

Compare Intarcia Therapeutics to Competitors

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

M
MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.